Analyst firms · UBS · ABT

UBS ABT price target and rating history

Abbott Laboratories (ABT) · Health Care

UBS rates Abbott Laboratories (ABT) Buy with a $130 price target, as of its latest action on Apr 20, 2023. It has published 3 rating actions on ABT since January 2022, including 0 upgrades and 0 downgrades. Across 5 firms with a ABT price target in the last 12 months, the median target is $121.

Current rating

Buy

Price target

$130

Median target, all firms

$121

Actions on ABT

3

UBS price target on ABT

Every UBS rating on ABT

• Apr 20, 2023
  ReiterateUBS raises its price target to $130 from $117, keeps Buy
• Mar 29, 2023
  InitiateUBS starts coverage at Buy, price target $117
• Jan 27, 2022
  ReiterateUBS raises its price target to $142 from $138, keeps Buy

How other firms rate ABT

Each firm's latest rating and stated target in the last 12 months.

Questions about UBS and ABT

What is UBS's price target for ABT?

UBS's latest stated price target for Abbott Laboratories (ABT) is $130, from its action on Apr 20, 2023.

What is UBS's rating on ABT?

UBS rates ABT Buy, a bullish rating, as of Apr 20, 2023.

When did UBS last change its view on ABT?

On Apr 20, 2023, UBS raises its price target to $130 from $117, keeps Buy.

How does UBS's ABT target compare with other analysts?

Across 5 firms with a ABT price target in the last 12 months, the median target is $121.

More ABT rating histories

• Barclays3
• Wolfe Research4
• Leerink Partners3
• Morgan Stanley5
• Raymond James5

All UBS ratingsABT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.